E
Tenax Therapeutics, Inc. TENX
$12.79 -$0.21-1.62% NASDAQ
Recommendation
Dividend Power Score
Prev Close
$13.00
Volume
159,836
Avg Vol (90D)
183,326
Market Cap
$527.41M
Dividend & Yield
--
52-Week Range
$4.63 - $18.38
P/E (TTM)
--
EPS (TTM)
-$1.13
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
Tenax Therapeutics (NASDAQ:TENX) Shares Pass Above 200 Day Moving Average - Should You Sell?
2/5/2026 - MarketBeat
Tenax Therapeutics to Participate in the Guggenheim Emerging Outlook Biotech Summit 2026
2/4/2026 - Globe Newswire
Tenax Therapeutics (NASDAQ:TENX) Shares Pass Above 200-Day Moving Average - Here's Why
1/28/2026 - MarketBeat
Tenax Therapeutics (NASDAQ:TENX) Share Price Passes Above Two Hundred Day Moving Average - Here's What Happened
1/13/2026 - MarketBeat
Tenax Therapeutics (NASDAQ:TENX) Is In A Good Position To Deliver On Growth Plans
1/10/2026 - Simply Wall St
Tenax Therapeutics Updates Chief Medical Officer Agreement
1/9/2026 - TipRanks Financial Blog
Tenax Therapeutics: A Speculative Buy
1/9/2026 - Seeking Alpha - Long Ideas
Tenax Therapeutics: A Speculative Buy
1/9/2026 - SeekingAlpha
Guggenheim Doubles Tenax (TENX) PT, Names Stock Top Pick
1/8/2026 - Insider Monkey
9 Best Performing Micro Cap Stocks in 2025
1/7/2026 - Insider Monkey
Tenax Therapeutics: How Lower Variance In Phase 3 Has "Loaded The Dice" For An Asymmetric Repricing
1/5/2026 - Seeking Alpha: Editor's Picks
Tenax Therapeutics: How Lower Variance In Phase 3 Has "Loaded The Dice" For An Asymmetric Repricing
1/5/2026 - Seeking Alpha - Long Ideas
Tenax Therapeutics: How Lower Variance In Phase 3 Has "Loaded The Dice" For An Asymmetric Repricing
1/5/2026 - SeekingAlpha
Tenax Therapeutics (NASDAQ:TENX) Stock Price Crosses Above 200 Day Moving Average - Here's Why
1/3/2026 - MarketBeat
Tenax Therapeutics (NASDAQ:TENX) Shares Pass Above 200 Day Moving Average - What's Next?
12/27/2025 - Ticker Report
Tenax Therapeutics (NASDAQ:TENX) Stock Crosses Above 200-Day Moving Average - Here's What Happened
12/26/2025 - MarketBeat
Tenax Therapeutics (NASDAQ:TENX) Stock Crosses Above 200 Day Moving Average - What's Next?
12/18/2025 - MarketBeat
Tenax Therapeutics Advances Phase 3 Study on Levosimendan for PH-HFpEF
12/17/2025 - TipRanks Financial Blog
Tenax Therapeutics (TENX) Updates on Clinical Trials and New Initiatives
12/17/2025 - GuruFocus
Tenax Therapeutics Announces Result of Prespecifed Blinded Sample Size Assessment
12/17/2025 - GuruFocus
Tenax Therapeutics reports result of prespecified blinded sample size assessment
12/17/2025 - The Fly
Tenax Therapeutics Announces Result of Prespecifed Blinded Sample Size Assessment
12/17/2025 - Globe Newswire
Tenax Therapeutics (TENX): Analyst Raises Target Price to $25 TENX Stock News
12/17/2025 - GuruFocus
Tenax Therapeutics price target raised by $11 at Guggenheim, here's why
12/17/2025 - The Fly
JANUS HENDERSON GROUP PLC Acquires Additional Shares in Tenax Therapeutics Inc
12/13/2025 - GuruFocus
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$7.29M
EBIT (TTM)
-$47.23M
Net Income (TTM)
-$43.33M
Balance Sheet
Total Assets (Q)
$102.81M
Total Debt (Q)
$0.00
Total Liabilities (Q)
$6.60M
Book Value Per Share (Q)
$2.39
Cash Flow
Cash from Operations (TTM)
-$25.91M
Cash from Investing (TTM)
--
Cash from Financing (TTM)
$26.97M
Net Change in Cash (TTM)
$1.06M
Filings
Filing Date
Wednesday, November 12, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
Week of Mar 23 and 27 (est)
Price History
Loading...
Beta
0.57
7-Day Total Return
2.24%
30-Day Total Return
0.95%
60-Day Total Return
82.98%
90-Day Total Return
67.85%
Year to Date Total Return
15.75%
1-Year Total Return
64.82%
2-Year Total Return
164.80%
3-Year Total Return
-85.60%
5-Year Total Return
-99.70%
52-week Low
Apr 22, 2025 - $4.63
52-week High
Jan 14, 2026 - $18.38
Valuation
Market Cap
$527.41M - Small Cap
Enterprise Value
$428.05M
Price/Sales (TTM)
--
Price/Book (Q)
5.44
Dividends and Shares
Shares Outstanding
39.74M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.tenaxthera.com
Phone Number
919 855 2100
Address
101 Glen Lennox Drive
Chapel Hill, NC 27517
Country
United States
Year Founded
1967
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Tenax Therapeutics, Inc., a clinical-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that... more
NASDAQ 02/10/2026 4:00PM Eastern Quotes delayed